An increase in life expectancy
Keeping pharmaceutical products economically viable is increasingly more complicated than simply making sure your patents are still valid, writes Donald Beers
‘Life cycle management’ has become a popular term in the pharmaceutical industry. While the industry focuses on extending and improving the lives of patients, in this case the ‘life cycle’ involved is the economically productive life of a pharmaceutical product. That life begins with regulatory approval and, to a significant extent, ends at the point at which a generic competitor is able to enter the market and sell the drug at a lower cost. The length of that life is crucial in valuing the products of a pharmaceutical company and, where flagship products are involved, in valuing the company as well.
This premium content is reserved for
Legal Week Subscribers.
A PREMIUM SUBSCRIPTION PROVIDES:
- Trusted insight, news and analysis from the UK and across the globe
- Connections to senior business lawyers within the leading law firms and legal departments
- Unique access to ALM's unrivalled, market-leading reporting in the US and Asia and cutting-edge research, including Legal Week's UK Top 50 and Global 100 rankings
- The Legal Week Daily News Alert, Editor's Highlights, and Breaking News digital newsletters and more, plus a choice of over 70 ALM newsletters
- Optimized access on all of your devices: desktop, tablet and mobile
- Complete access to the site's full archive of more than 56,000 articles
Already have an account? Sign In Now
For enterprise-wide or corporate enquiries, please contact Paul Reeves on Preeves@alm.com or call on +44 (0) 203 875 0651